MARKET

OCUL

OCUL

Ocular Therapeut
NASDAQ
10.75
+0.69
+6.86%
After Hours: 10.99 +0.24 +2.23% 19:51 03/01 EST
OPEN
10.15
PREV CLOSE
10.06
HIGH
10.91
LOW
10.03
VOLUME
2.61M
TURNOVER
0
52 WEEK HIGH
10.91
52 WEEK LOW
1.995
MARKET CAP
1.23B
P/E (TTM)
-12.4263
1D
5D
1M
3M
1Y
5Y
Criteo, Ocular Therapeutix, and More Stocks See Action From Activist Investors
Activist investor Petrus Advisers raised its stake in advertising-technology firm Criteo. Ocular Therapeutix Summer Road raised its position in the eye-disease-focused biotech. Appian and Fortrea Holdings have seen their shares drop in value.
Barron‘s · 17h ago
$7M Bet On Ocular Therapeutix? Check Out These 3 Stocks Insiders Are Buying
U.S. Stocks closed mixed on Tuesday but there were a few notable insider trades. V.F. Corporation and Western Midstream Partners made notable insider purchases. Insider purchases indicate confidence in the company's prospects or that they view the stock as a bargain. VF Corporation and Ocular Therapeutix made notable purchases.
Benzinga · 3d ago
Piper Sandler Maintains Overweight Rating for Ocular Therapeutix: Here's What You Need To Know
Shares of Ocular Therapeutix are trading up 1.22% over the last 24 hours. Piper Sandler has maintained its Overweight rating and raised its price target from $10.00 to $15.00. The company is a biotechnology company that specializes in therapies for diseases and conditions of the eye.
Benzinga · 5d ago
Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
NASDAQ · 5d ago
Piper Sandler Maintains Overweight on Ocular Therapeutix, Raises Price Target to $15
Benzinga · 5d ago
Weekly Report: what happened at OCUL last week (0219-0223)?
Weekly Report · 5d ago
Ocular Therapeutix Poised for Growth with Strategic Leadership Hires and Strong Financial Position
Analyst Colleen M. Kusy of Robert W. Baird reiterated a Buy rating on Ocular Therapeutix (OCUL) with a price target of $18.00. The company is developing a treatment for wet AMD. Corporate insider sentiment is positive on the stock.
TipRanks · 5d ago
Strategic Leadership and Strong Financials Bolster Buy Rating for Ocular Therapeutix
TipRanks · 02/23 10:19
More
About OCUL
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of therapies for diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is developed for the treatment of ocular inflammation and pain ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Its earlier stage development assets include: axitinib intravitreal implant (OTX-TKI), is under Phase I clinical trials for the treatment of wet age-related macular degeneration (AMD) and diabetic retinopathy; travoprost intracameral implant (OTX-TIC), is under Phase II clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension; and dexamethasone intracanalicular insert (OTX-DED), for the short-term treatment of the signs and symptoms of dry eye disease; and cyclosporine intracanalicular insert (OTX-CSI), for the chronic treatment of dry eye disease, both of which have completed Phase II clinical trials.

Webull offers Ocular Therapeutix Inc stock information, including NASDAQ: OCUL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OCUL stock methods without spending real money on the virtual paper trading platform.